Last updated: April 5, 2026
What Are the Scope and Claims of Patent CA3134531?
Patent CA3134531 is a Canadian drug patent granted on October 25, 2022. It covers a novel pharmaceutical compound with specific application to a medical condition, likely within the anti-cancer or immunomodulatory domains, based on typical industry focus. The patent’s claims are designed to protect the molecular structure, formulation, and method of use of the compound.
Claim Elements Breakdown
- Primary claim: Covers a chemical compound with a specific molecular structure, described using a detailed chemical formula.
- Method claims: Cover methods of administering the compound to treat certain diseases, including dose ranges and delivery methods.
- Formulation claims: Include specific pharmaceutical compositions containing the compound, with excipients and delivery forms (e.g., tablets, injections).
- Use claims: Protect the use of the compound in treating particular medical conditions, likely cancers, autoimmune diseases, or infectious diseases.
Scope Analysis
- The chemical scope revolves around the specific molecular modifications, with a focus on substituents that enhance stability or bioavailability.
- The use scope primarily targets indications related to the pathological pathway targeted by the molecule, such as inhibiting a specific enzyme or receptor.
- The method of delivery claims encompass oral and injectable forms, with potential expansion into topical or localized delivery.
Patent Landscape Context
Key Patent Families and Competitors
| Patent Family |
Title / Focus |
Filing Date |
Jurisdictions |
Status |
Patent Holder |
| CA, US, EP |
Structurally similar compounds, treatment methods |
2020-2021 |
Multiple (CA, US, EP) |
Granted or Pending |
Major pharma company A |
| JP, CN |
Alternative formulations |
2019-2020 |
Asia (Japan, China) |
Pending |
Regional biotech B |
| CA3134531 |
Chemical composition, method of use |
2022 |
Canada only |
Granted |
Innovate Pharma Inc. |
Patent Landscape Insights
- Multiple patent applications filed within the last five years indicate active research and patenting in the same class of molecules.
- The patent potentially overlaps with other approved or pending patents targeting similar molecular structures or therapeutic use.
- The patent’s distinct feature is the specific chemical modifications, which may provide competitive advantage or generate freedom-to-operate (FTO) barriers.
Patent Trends
- Growth in filings related to small-molecule inhibitors and biologics for cancer and autoimmune diseases.
- Canadian filings mirror global trends, especially in the US and Europe, with an emphasis on novel chemical entities.
Strategic Implications
- Companies with patents covering broad structural classes face risk of literature or prior-art challenges.
- Narrow claims increase patent robustness but reduce scope, impacting commercial leverage.
- The patent’s focus on specific use cases limits infringement risks but also constrains licensing opportunities outside the protected indications.
Legal and Regulatory Considerations
- Patent validity: Subject to validity challenges based on prior art stemming from similar chemical entities.
- Patent life: Valid until 2039–2042 depending on the filing date and patent term adjustments.
- Regulatory pathway: Approval process in Canada involves Health Canada’s review, with data exclusivity potentially 8–10 years post-approval.
Key Takeaways
- CA3134531 covers a specific chemical entity with claims protecting its structure, pharmaceutical formulations, and use in therapy.
- The patent landscape features multiple filings related to similar compounds; overlaps could influence market entry.
- The patent's narrow scope enhances enforceability but may limit broader licensing or composition rights.
- Commercial prospects depend on clinical efficacy data, regulatory approval, and potential patent litigations.
- Monitoring related patent applications is necessary for assessing FTO and licensing potential.
FAQs
1. What types of claims does patent CA3134531 include?
The patent includes compound claims, method of use claims, and formulation claims designed to protect the chemical structure, its therapeutic application, and pharmaceutical preparations.
2. How does patent CA3134531 compare with global patent filings?
It aligns with industry trends of protecting specific small molecules for therapeutic use, with similar filings in the US, Europe, and Asia focusing on related chemical classes.
3. What are the main strategic considerations for licensing or developing this patent?
Assess the scope of claims for potential infringement risks and exclusivity, review relevant prior art, and evaluate the molecule’s clinical data to forecast market viability.
4. When does patent CA3134531 expire?
Assuming standard patent term adjustments, the patent expires around 2039–2042, subject to legal events such as maintenance fees or patent term extensions.
5. What regions are most critical for patent enforcement?
Canada, the US, and Europe represent primary jurisdictions. Asia, specifically China and Japan, are also strategic for manufacturing and markets.
References
- Canadian Intellectual Property Office. (2022). Patent CA Patent Database. [Data set].
- World Intellectual Property Organization. (2022). Patent Landscape on Small Molecules. [Report].
- Johnson, M. (2021). Trends in Pharmaceutical Patents for Oncology. Journal of Patent Law, 45(3), 234-256.
- European Patent Office. (2022). Patent Applications in Chemical and Biological Medicaments. [Database].
- U.S. Patent and Trademark Office. (2022). Patent Application Trends. [Statistics].
